Exagen Statistics
Total Valuation
Exagen has a market cap or net worth of $30.92 million. The enterprise value is $26.70 million.
| Market Cap | 30.92M |
| Enterprise Value | 26.70M |
Important Dates
The next estimated earnings date is Monday, August 5, 2024, before market open.
| Earnings Date | Aug 5, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Exagen has 17.37 million shares outstanding. The number of shares has increased by 2.38% in one year.
| Shares Outstanding | 17.37M |
| Shares Change (YoY) | +2.38% |
| Shares Change (QoQ) | +0.60% |
| Owned by Insiders (%) | 28.31% |
| Owned by Institutions (%) | 56.86% |
| Float | 7.02M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.55 |
| Forward PS | 0.54 |
| PB Ratio | 1.55 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.48 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.83, with a Debt / Equity ratio of 1.15.
| Current Ratio | 4.83 |
| Quick Ratio | 4.35 |
| Debt / Equity | 1.15 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7.61 |
Financial Efficiency
Return on equity (ROE) is -75.90% and return on invested capital (ROIC) is -42.14%.
| Return on Equity (ROE) | -75.90% |
| Return on Assets (ROA) | -33.30% |
| Return on Capital (ROIC) | -42.14% |
| Revenue Per Employee | $320,305 |
| Profits Per Employee | -$111,270 |
| Employee Count | 174 |
| Asset Turnover | 0.96 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Exagen has paid $33,000 in taxes.
| Income Tax | 33,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -39.25% in the last 52 weeks. The beta is 1.30, so Exagen's price volatility has been higher than the market average.
| Beta (5Y) | 1.30 |
| 52-Week Price Change | -39.25% |
| 50-Day Moving Average | 1.76 |
| 200-Day Moving Average | 1.82 |
| Relative Strength Index (RSI) | 40.02 |
| Average Volume (20 Days) | 21,236 |
Short Selling Information
The latest short interest is 22,319, so 0.13% of the outstanding shares have been sold short.
| Short Interest | 22,319 |
| Short Previous Month | 24,064 |
| Short % of Shares Out | 0.13% |
| Short % of Float | 0.32% |
| Short Ratio (days to cover) | 0.39 |
Income Statement
In the last 12 months, Exagen had revenue of $55.73 million and -$19.36 million in losses. Loss per share was -$1.09.
| Revenue | 55.73M |
| Gross Profit | 32.75M |
| Operating Income | -18.13M |
| Pretax Income | -19.33M |
| Net Income | -19.36M |
| EBITDA | -14.09M |
| EBIT | -17.08M |
| Loss Per Share | -$1.09 |
Balance Sheet
The company has $27.27 million in cash and $23.04 million in debt, giving a net cash position of $4.23 million or $0.24 per share.
| Cash & Cash Equivalents | 27.27M |
| Total Debt | 23.04M |
| Net Cash | 4.23M |
| Net Cash Per Share | $0.24 |
| Equity (Book Value) | 19.99M |
| Book Value Per Share | 1.15 |
| Working Capital | 33.62M |
Cash Flow
In the last 12 months, operating cash flow was -$13.75 million and capital expenditures -$494,000, giving a free cash flow of -$14.25 million.
| Operating Cash Flow | -13.75M |
| Capital Expenditures | -494,000 |
| Free Cash Flow | -14.25M |
| FCF Per Share | -$0.79 |
Margins
Gross margin is 58.76%, with operating and profit margins of -32.54% and -34.74%.
| Gross Margin | 58.76% |
| Operating Margin | -32.54% |
| Pretax Margin | -34.68% |
| Profit Margin | -34.74% |
| EBITDA Margin | -25.28% |
| EBIT Margin | -30.65% |
| FCF Margin | -25.56% |
Dividends & Yields
Exagen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.38% |
| Shareholder Yield | -2.38% |
| Earnings Yield | -62.61% |
| FCF Yield | -46.07% |
Analyst Forecast
The average price target for Exagen is $7.00, which is 293.26% higher than the current price. The consensus rating is "Buy".
| Price Target | $7.00 |
| Price Target Difference | 293.26% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | 14.15% |
| EPS Growth Forecast (5Y) | -13.30% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Exagen has an Altman Z-Score of -6.4 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.4 |
| Piotroski F-Score | 4 |